Dynamics of antiviral-resistant influenza viruses in the Netherlands, 2005-2008

Antiviral Research

Volumn 83, Issue 3, 2009, Pages 290-297

  Jonges, M ^a,b   van der Lubben, I M ^a   Dijkstra, F ^a   Verhoef, L ^a   Koopmans, M ^a,b   Meijer, A ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Amantadine; Antiviral resistance; Influenza; Oseltamivir; Surveillance; Zanamivir

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; ADAMANTANE DERIVATIVE; AMANTADINE; ANTIVIRUS AGENT; OSELTAMIVIR; PROTEIN M2; RIMANTADINE; SIALIDASE INHIBITOR; ZANAMIVIR;

ANIMAL CELL; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CONTROLLED STUDY; DYNAMICS; HUMAN; INFLUENZA; INFLUENZA VIRUS; INFLUENZA VIRUS A; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS B; MONITORING; NETHERLANDS; NONHUMAN; PHENOTYPE; PHYLOGENY; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; SYMPTOM; VIRUS DETECTION; VIRUS ISOLATION; VIRUS MUTATION;

ADAMANTANE; ANTIVIRAL AGENTS; CLUSTER ANALYSIS; DRUG RESISTANCE, VIRAL; HUMANS; INFLUENZA A VIRUS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA, HUMAN; MICROBIAL SENSITIVITY TESTS; MUTATION, MISSENSE; NETHERLANDS; PHYLOGENY; RNA, VIRAL; SEQUENCE ANALYSIS, DNA; SEQUENCE HOMOLOGY, AMINO ACID;

HUMAN INFLUENZA VIRUS; ORTHOMYXOVIRIDAE;

EID: 68249118725     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2009.07.003     Document Type: Article

References (40)

1. Aoki F.Y., Boivin G., and Roberts N. Influenza virus susceptibility and resistance to oseltamivir. Antiviral Ther. 12 (2007) 603-616
2. Belshe R.B., Smith M.H., Hall C.B., Betts R., and Hay A.J. Genetic basis of resistance to rimantadine emerging during treatment of influenza virus infection. J. Virol. 62 (1988) 1508-1512
3. Besselaar T.G., Naidoo D., Buys A., Gregory V., McAnerney J., Manamela J.M., Blumberg L., and Schoub B.D. Widespread oseltamivir resistance in influenza A viruses (H1N1), South Africa. Emerg. Infect. Dis. 14 (2008) 1809-1810
4. Bright R.A., Medina M.J., Xu X., Perez-Oronoz G., Wallis T.R., Davis X.M., Povinelli L., Cox N.J., and Klimov A.I. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 366 (2005) 1175-1181
5. Cady S.D., and Hong M. Amantadine-induced conformational and dynamical changes of the influenza M2 transmembrane proton channel. Proc. Natl. Acad. Sci. U.S.A. 105 (2008) 1483-1488
6. Dharan N.J., Gubareva L.V., Meyer J.J., Okomo-Adhiambo M., McClinton R.C., Marshall S.A., St. George K., Epperson S., Brammer L., Klimov A.I., Bresee J.S., and Fry A.M. Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. JAMA 301 (2009) 1034-1041
7. Donker, G.A., 2007. Continue Morbiditeits Registratie Peilstations Nederland 2006, NIVEL.
8. Duwe S., and Schweiger B. A new and rapid genotypic assay for the detection of neuraminidase inhibitor resistant influenza A viruses of subtype H1N1, H3N2, and H5N1. J. Virol. Methods 153 (2008) 134-141
9. Fouchier R.A., Bestebroer T.M., Herfst S., Van Der Kemp L., Rimmelzwaan G.F., and Osterhaus A.D. Detection of influenza A viruses from different species by PCR amplification of conserved sequences in the matrix gene. J. Clin. Microbiol. 38 (2000) 4096-4101
10. Furuse Y., Suzuki A., Kamigaki T., Shimizu M., Fuji N., and Oshitani H. Reversion of influenza A (H3N2) virus from amantadine resistant to amantadine sensitive by further reassortment in Japan during the 2006-2007 influenza season. J. Clin. Microbiol. 47 (2009) 841-844
11. Gerdil C. The annual production cycle for influenza vaccine. Vaccine 21 (2003) 1776-1779
12. Goddard N., Zucs P., Ciancio B., Plata F., Hungnes O., Mazick A., Meijer A., Hay A., Daniels R., Nicoll A., and Zambon M. Start of the influenza season 2008-9 in Europe-increasing influenza activity moving from West to East dominated by A(H3N2). Euro. Surveill. 14 (2009) pii: 19097
13. Gubareva L.V., Kaiser L., Matrosovich M.N., Soo-Hoo Y., and Hayden F.G. Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. J. Infect. Dis. 183 (2001) 523-531
14. Hauge S.H., Dudman S., Borgen K., Lackenby A., and Hungnes O. Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007-08. Emerg. Infect. Dis. 15 (2009) 155-162
15. Hay, A.J., Daniels, R., Lin, Y.P., Zheng, X., Gregory, V., Bennett, M., Whittaker, L., 2007. Characteristics of human influenza A(H1N1), A(H3N2) and B viruses isolated February to August 2007. Interim Report. Mill Hill, London, WHO Collaborating Centre for Reference and Research on Influenza, National Institute for Medical Research.
16. Hay A.J., Wolstenholme A.J., Skehel J.J., and Smith M.H. The molecular basis of the specific anti-influenza action of amantadine. EMBO J. 4 (1985) 3021-3024
17. Hay A.J., Zambon M.C., Wolstenholme A.J., Skehel J.J., and Smith M.H. Molecular basis of resistance of influenza A viruses to amantadine. J. Antimicrob. Chemother. 18 Suppl. B (1986) 19-29
18. Hayden F.G., and Hay A.J. Emergence and transmission of influenza A viruses resistant to amantadine and rimantadine. Curr. Top. Microbiol. Immunol. 176 (1992) 119-130
19. Herlocher M.L., Carr J., Ives J., Elias S., Truscon R., Roberts N., and Monto A.S. Influenza virus carrying an R292K mutation in the neuraminidase gene is not transmitted in ferrets. Antiviral Res. 54 (2002) 99-111
20. Herlocher M.L., Truscon R., Elias S., Yen H.L., Roberts N.A., Ohmit S.E., and Monto A.S. Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets. J. Infect. Dis. 190 (2004) 1627-1630
21. Inoue Y., Yoneda M., and Kitahori Y. Dual mutations in the HA1 peptide of amantadine-resistant influenza viruses at positions 193 and 225. Jpn. J. Infect. Dis. 60 (2007) 147-148
22. Ives J.A., Carr J.A., Mendel D.B., Tai C.Y., Lambkin R., Kelly L., Oxford J.S., Hayden F.G., and Roberts N.A. The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. Antivir. Res. 55 (2002) 307-317
23. Kramarz P., Monnet D., Nicoll A., Yilmaz C., and Ciancio B. Use of oseltamivir in 12 European countries between 2002 and 2007-lack of association with the appearance of oseltamivir-resistant influenza A(H1N1) viruses. Euro. Surveill. 14 (2009) pii: 19112
24. Lackenby A., Democratis J., Siqueira M.M., and Zambon M.C. Rapid quantitation of neuraminidase inhibitor drug resistance in influenza virus quasispecies. Antivir. Ther. 13 (2008) 809-820
25. Massart D.L., Smeyers-Verbeke J., Capron X., and Schlesier K. Visual presentation of data by means of box plots. LC·GC Europe 18 (2005) 215-218
26. Meijer A., Lackenby A., Hungnes O., Lina B., Van-Der-Werf S., Schweiger B., Opp M., Paget J., van-de-Kassteele J., Hay A., and Zambon M. Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007-08 season. Emerg. Infect. Dis. 15 (2009) 552-560
27. Meijer A., Van De Kamp E., Koch G., and Kimman T.G. Cell-ELISA for antiviral susceptibility testing of influenza virus: performance depends on the compatibility of virus strain and type of MDCK cells. In: Kawaoka Y. (Ed). Proceedings of the International Conference on Options for the Control of Influenza Virus. International Congress Series, vol. 1263 (2004), Elsevier, Amsterdam 491-494
28. Molinari N.A., Ortega-Sanchez I.R., Messonnier M.L., Thompson W.W., Wortley P.M., Weintraub E., and Bridges C.B. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine 25 (2007) 5086-5096
29. Monto A.S., McKimm-Breschkin J.L., Macken C., Hampson A.W., Hay A., Klimov A., Tashiro M., Webster R.G., Aymard M., Hayden F.G., and Zambon M. Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob. Agents Chemother. 50 (2006) 2395-2402
30. Potier M., Mameli L., Bélisle M., Dallaire L., and Melançon S.B. Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl-alpha-d-N-acetylneuraminate) substrate. Anal. Biochem. 94 (1979) 287-296
31. Rameix-Welti M.A., Enouf V., Cuvelier F., Jeannin P., and van der Werf S. Enzymatic properties of the neuraminidase of seasonal H1N1 influenza viruses provide insights for the emergence of natural resistance to oseltamivir. PLoS Pathog. 4 (2008) e1000103
32. Saito R., Li D., Shimomura C., Masaki H., Le M.Q., Nguyen H.L., Nguyen H.T., Phan T.V., Nguyen T.T., Sato M., Suzuki Y., and Suzuki H. An off-seasonal amantadine-resistant H3N2 influenza outbreak in Japan. Tohoku J. Exp. Med. 210 (2006) 21-27
33. Simonsen L., Viboud C., Grenfell B.T., Dushoff J., Jennings L., Smit M., Macken C., Hata M., Gog J., Miller M.A., and Holmes E.C. The genesis and spread of reassortment human influenza A/H3N2 viruses conferring adamantane resistance. Mol. Biol. Evol. 24 (2007) 1811-1820
34. Sweet C., Hayden F.G., Jakeman K.J., Grambas S., and Hay A.J. Virulence of rimantadine-resistant human influenza A (H3N2) viruses in ferrets. J. Infect. Dis. 164 (1991) 969-972
35. Tamura D., Mitamura K., Yamazaki M., Fujino M., Nirasawa M., Kimura K., Kiso M., Shimizu H., Kawakami C., Hiroi S., Takahashi K., Hata M., Minagawa H., Kimura Y., Kaneda S., Sugita S., Horimoto T., Sugaya N., and Kawaoka Y. Oseltamivir-resistant influenza A viruses circulating in Japan. J. Clin. Microbiol. 47 (2009) 1424-1427
36. van Gageldonk-Lafeber A.B., van der Sande M.A., Heijnen M.L., Peeters M.F., Bartelds A.I., and Wilbrink B. Risk factors for acute respiratory tract infections in general practitioner patients in The Netherlands: a case-control study. BMC Infect. Dis. 7 (2007) 35
37. Varghese J.N., and Colman P.M. Three-dimensional structure of the neuraminidase of influenza virus A/Tokyo/3/67 at 2.2 A resolution. J. Mol. Biol. 221 (1991) 473-486
38. Yen H.L., Herlocher L.M., Hoffmann E., Matrosovich M.N., Monto A.S., Webster R.G., and Govorkova E.A. Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility. Antimicrob. Agents Chemother. 49 (2005) 4075-4084
39. Yen H.L., Hoffmann E., Taylor G., Scholtissek C., Monto A.S., Webster R.G., and Govorkova E.A. Importance of neuraminidase active-site residues to the neuraminidase inhibitor resistance of influenza viruses. J. Virol. 80 (2006) 8787-8795
40. Ziegler T., Hemphill M.L., Ziegler M.L., Perez-Oronoz G., Klimov A.I., Hampson A.W., Regnery H.L., and Cox N.J. Low incidence of rimantadine resistance in field isolates of influenza A viruses. J. Infect. Dis. 180 (1999) 935-939